Clinical Trial Update: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Leuprolide acetate 45 mg, a 6-month formulation, in children with central precocious puberty has completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• Leuprolide acetate (Leuprolide acetate)

Snippet

Sponsor: AbbVie | Conditions: Central Precocious Puberty (CPP) | Phase 3 | Status: COMPLETED | Results posted: 2023-05-16